Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunodeficiency Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Connecting Youth and Young Adults to Optimize ART Adherence: YouTHrive Efficacy Trial

NCT03149757
View directory record Official record
Conditions
HIV Infections
Interventions
YouTHrive, Information-only Control
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 24 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 21, 2026, 12:56 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations

NCT03278912
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Not applicable Interventional

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

NCT00100581
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Efavirenz, Lamivudine, Lopinavir/ritonavir, Pegylated interferon alfa-2a, Ribavirin, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 21, 2026, 12:56 PM EDT
Not yet recruiting Not applicable Interventional

PositiveLinks for Youth (PL4Y) for Texas

NCT07804602
View directory record Official record
Conditions
Human Immunodeficiency Virus, HIV
Interventions
PositiveLinks for Youth Smartphone App
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 29 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 2 Interventional

Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist

NCT00001475
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection
Interventions
IL-2 plus Anti-TNF or Thalidomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 2 Interventional

Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.

NCT00002167
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tin ethyl etiopurpurin
Drug
Lead sponsor
Clinical Solutions
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Men's Prevention Apps to Research Efficacy

NCT03965221
View directory record Official record
Conditions
HIV/AIDS, Sexually Transmitted Diseases, Pre-exposure Prophylaxis, Risk Reduction
Interventions
LYNX, MyChoices
Behavioral
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
15 Years to 29 Years · Male only
Enrollment
381 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Not applicable Interventional Results available

Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression

NCT00709111
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

NCT00924898
View directory record Official record
Conditions
Acute HIV Infection, HIV Infections
Interventions
efavirenz, emtricitabine, and tenofovir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Not applicable Interventional

Multidisciplinary Inpatient Palliative Care Intervention

NCT00325611
View directory record Official record
Conditions
Cerebrovascular Accident, Cancer, Coronary Arteriosclerosis, Heart Failure, Congestive, Diabetes Mellitus, Acquired Immunodeficiency Syndrome, Failure to Thrive, Pulmonary Disease, Chronic Obstructive, Dementia, Kidney Failure, Chronic, Pneumonia, Liver Failure, Renal Failure, Respiratory Failure, Stroke
Interventions
Multidisciplinary palliative care team met with patient
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2006 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

NCT00135434
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir/Ritonavir/Lopinavir/ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2011 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers

NCT00001992
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1IIIB
Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 12:56 PM EDT
Recruiting No phase listed Observational

Biologics And Clinical Immunology Cohort at Sinai

NCT04784364
View directory record Official record
Conditions
Immunological Disease, Autoimmune Diseases, Primary Immune Deficiency
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 12:56 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Medical Mistrust Among Hispanic/Latino Gay, Bisexual and Other Men Who Have Sex With Men (HLMSM)

NCT06132672
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Navigators (peer navigator) training, delayed-intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 2 Interventional

A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT

NCT00001032
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
44
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Dolutegravir and Prednisone

NCT01425099
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir, Prednisone
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis

NCT00002316
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Lobradimil, Amphotericin B
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 12:56 PM EDT
Completed No phase listed Observational

Novel Therapy for Glucose Intolerance in HIV Disease

NCT02006914
View directory record Official record
Conditions
Insulin Resistance
Interventions
Chromium Picolinate
Dietary Supplement
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 2 Interventional

Kidney Transplant for HIV-Infected Patients in Renal Failure

NCT00009009
View directory record Official record
Conditions
Chronic Kidney Failure, HIV Infection
Interventions
immunosuppressive regimen designed to complement HAART
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 1 Interventional

A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP

NCT00000998
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1989
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 12:56 PM EDT
Completed No phase listed Observational

A Study of the Long-Term Outcomes of HIV-Positive Patients

NCT00000932
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
3,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
91
States / cities
Mill Valley, California • Oakland, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

NCT02915016
View directory record Official record
Conditions
HIV Infections
Interventions
DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

NCT00000893
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 21, 2026, 12:56 PM EDT
Completed Phase 2 Interventional

Investigator-Sponsored Protocol - Continued Use of Ibalizumab

NCT01056393
View directory record Official record
Conditions
HIV Infections
Interventions
ibalizumab 800mg Q2Weeks, ibalizumab 2000mg Q4Weeks
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 21, 2026, 12:56 PM EDT